PCOS Hair Loss: Why It Happens and How to Treat Androgenic Alopecia in Women

PCOS Hair Loss: Why It Happens and How to Treat Androgenic Alopecia in Women

Hair thinning is one of the most distressing — and often least talked about — symptoms of polycystic ovary syndrome. If you've noticed more strands on your pillow, a widening part, or a ponytail that feels noticeably thinner, you're not imagining it. PCOS hair loss is real, it has a clear biological mechanism, and — critically — it is treatable.

This article explains why PCOS causes androgenic alopecia in women, what the evidence says about the most effective treatments, and what questions to ask your doctor.

What Is PCOS Androgenic Alopecia?

Androgenic alopecia (AGA) — also called female pattern hair loss (FPHL) — is characterised by progressive thinning of the scalp hair in a diffuse pattern, typically starting at the crown and the central parting. In women with PCOS, this thinning is driven by hormonal imbalance: specifically, elevated levels of androgens (male-pattern hormones) that miniaturise hair follicles over time.

PCOS affects an estimated 8–13% of women of reproductive age worldwide, making it the most common endocrine disorder in this population (Teede et al., Human Reproduction, 2018). Of those, studies suggest that up to 70–80% have evidence of biochemical or clinical hyperandrogenism — and hair loss is one of its most visible consequences (Azziz et al., Journal of Clinical Endocrinology & Metabolism, 2016).

Why Does PCOS Cause Hair Thinning?

The mechanism is well understood. Under normal hormonal conditions, hair follicles cycle through growth (anagen), transition (catagen), and rest (telogen) phases. Androgens — particularly dihydrotestosterone (DHT), converted from testosterone by the enzyme 5-alpha reductase — bind to androgen receptors in genetically susceptible follicles and progressively shorten the anagen (growth) phase. Follicles shrink with each cycle, producing finer, shorter hairs until they eventually stop producing visible hair altogether.

In women with PCOS, this process is accelerated by:

• Elevated free testosterone — reduced sex hormone-binding globulin (SHBG) means more testosterone is biologically active
• Elevated DHEA-S — an adrenal androgen that converts to testosterone peripherally
• Increased 5-alpha reductase activity — which converts more testosterone to the more potent DHT at the follicle level
• Insulin resistance — present in up to 70% of women with PCOS (Legro et al., Fertility and Sterility, 2013), which independently suppresses SHBG and amplifies androgen bioavailability

What makes PCOS hair loss particularly difficult is that it can begin even when blood androgen levels appear "normal" — because hair follicles may be hyperresponsive to androgens due to increased receptor sensitivity or local enzyme activity (Carmina & Lobo, Obstetrics & Gynecology Clinics, 2001).

How Is PCOS Hair Loss Diagnosed?

Diagnosis requires both a hormonal workup and a clinical scalp assessment.

Blood tests typically include:

• Total and free testosterone
• DHEA-S
• SHBG
• LH and FSH ratio
• Fasting insulin and glucose (HOMA-IR)
• Thyroid function (to rule out thyroid-related hair loss)
• Ferritin (iron deficiency is a common co-trigger)
• Prolactin

Scalp assessment tools include:

• Trichoscopy (dermoscopy of the scalp) — shows follicular miniaturisation and reduced hair shaft calibre
• The Ludwig Scale for female pattern hair loss classification
• Global photograph standardisation for tracking treatment response

The International PCOS Guideline Group (Teede et al., 2023, Nature Reviews Endocrinology) recommends that all women presenting with hirsutism, acne, or hair loss be evaluated for PCOS using the Rotterdam criteria — requiring two of three: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound.

Treatment Options for PCOS-Related Hair Loss

There is no single cure, but combination treatment targeting both the hormonal root cause and the follicle-level effects is consistently the most effective approach.

1. Anti-androgen medications

Spironolactone (50–200mg/day) is the most widely used anti-androgen for FPHL in premenopausal women. It blocks androgen receptors at the hair follicle and reduces adrenal androgen production. A 2020 systematic review in the Journal of the American Academy of Dermatology found meaningful hair density improvement in women treated with spironolactone over 12–24 months, with best results at higher doses (Famenini et al., 2015; Rathnayake & Sinclair, 2010).

Cyproterone acetate (available in some markets, including Singapore, as part of combined oral contraceptives such as Diane-35) offers both anti-androgenic and cycle-regulating effects. It is often considered first-line for women who also want contraception.

Oral contraceptive pills (OCPs) containing low-androgenic or anti-androgenic progestins suppress LH-driven ovarian androgen production and increase SHBG, reducing free testosterone. Pills with drospirenone, cyproterone acetate, or desogestrel are preferred over those with levonorgestrel or norethisterone, which have higher androgenic activity.

2. Topical minoxidil

Minoxidil remains the only topical treatment with robust evidence for FPHL regardless of aetiology. It prolongs the anagen phase and increases follicular size. The standard dose for women is 2% solution twice daily or 5% foam once daily. A randomised controlled trial (Journal of the American Academy of Dermatology, Messenger & Rundegren, 2004) demonstrated significant improvements in hair count and weight versus placebo after 48 weeks. Low-dose oral minoxidil (0.25–1.25mg/day) has emerged as an effective alternative with good tolerability in women (Randolph & Tosti, Journal of the American Academy of Dermatology, 2021).

3. Insulin sensitisers

In women with PCOS and insulin resistance, metformin can lower androgen levels by improving insulin sensitivity, reducing ovarian androgen production, and increasing SHBG. While not a direct hair loss treatment, it addresses an upstream driver. Some trials have shown modest improvements in hair scores when used alongside anti-androgens (Ibáñez et al., Journal of Clinical Endocrinology & Metabolism, 2002).

4. Nutritional and lifestyle interventions

• Iron optimisation: Ferritin below 40 ng/mL is associated with impaired hair regrowth (Rushton et al., Clinical and Experimental Dermatology, 2002). Supplementation to >70 ng/mL is often recommended.
• Low-GI diet: Reduces insulin spikes, attenuates androgen production, and supports SHBG.
• Inositol (myo-inositol + D-chiro-inositol): Evidence supports its role in improving insulin sensitivity and reducing free testosterone in PCOS (Unfer et al., Gynecological Endocrinology, 2017).
• Zinc: May inhibit 5-alpha reductase activity and has been studied in androgenic alopecia with modest positive results.
• Stress management: Cortisol drives adrenal androgen production; chronic stress amplifies the PCOS hormonal milieu.

5. Emerging therapies

Low-level laser therapy (LLLT) and platelet-rich plasma (PRP) scalp injections are gaining traction as adjunct treatments. PRP, which concentrates growth factors from autologous blood, has shown improvements in hair density in multiple small RCTs, though larger trials are needed (Gupta & Versteeg, Journal of Cutaneous and Aesthetic Surgery, 2019).

Setting Realistic Expectations

Hair regrowth from PCOS treatment is slow. Most anti-androgen treatments take 6–12 months to show measurable improvement, and minoxidil typically requires at least 4–6 months before results are visible. Patience — and consistent treatment — is essential. Stopping treatment prematurely almost always results in regression.

Tracking progress with standardised scalp photos every 8–12 weeks is more reliable than subjective perception, which is skewed by anxiety about hair loss.

The Psychological Impact

Research consistently finds that hair loss has a disproportionate psychological impact on women compared to men, with significant effects on self-esteem, social functioning, and quality of life (Cash et al., Journal of the American Academy of Dermatology, 2001; Fried, Journal of the American Academy of Dermatology, 2017). Addressing PCOS hair loss is not cosmetic vanity — it is a legitimate medical concern warranting proper clinical attention.

If you've been dismissed or told to "just use volumising shampoo," you deserve a second opinion from a clinician who understands the hormonal complexity of PCOS.

Frequently Asked Questions

Q: Can PCOS hair loss be reversed?
A: In many cases, yes — especially when caught early. Anti-androgen therapy can halt further miniaturisation, and with continued treatment, some follicle recovery is possible. The earlier treatment begins, the better the prognosis.

Q: Will my hair grow back after treating PCOS?
A: Treatment can stabilise loss and, in some cases, restore density — but results depend on how long hair loss has been present and how much follicle damage has occurred. Dormant follicles can often be reactivated; completely scarred follicles cannot.

Q: Is PCOS hair loss different from stress hair loss (telogen effluvium)?
A: Yes. Telogen effluvium is typically diffuse and triggered by a specific stressor (surgery, illness, crash dieting); it usually resolves within 3–6 months. PCOS androgenic alopecia follows a pattern distribution, progresses slowly, and does not self-resolve without hormonal intervention. The two can coexist.

Q: Does the contraceptive pill cause or worsen hair loss?
A: It depends on the pill. Pills with anti-androgenic progestins (drospirenone, cyproterone acetate) often improve PCOS hair loss. Pills with androgenic progestins (levonorgestrel, norethisterone) can worsen it. Check with your doctor before switching.

Q: How long does it take to see results from treatment?
A: Expect 6–12 months for meaningful visible improvement from anti-androgen medication. Minoxidil shows earlier results at 4–6 months. Progress tracking with photos is strongly recommended.

Q: Can diet alone treat PCOS hair loss?
A: Diet and lifestyle changes can improve the hormonal environment significantly — particularly for women with insulin-resistant PCOS — but they rarely reverse established hair loss on their own. They work best as adjuncts to medical treatment.

Take the Next Step

PCOS hair loss responds to treatment — but only with the right diagnosis and the right protocol. Zoey's clinicians specialise in women's hormonal health and can assess your androgens, design a personalised treatment plan, and support you through the process.

Start your PCOS hair loss assessment at zoey.sg →

References

1. Azziz R, et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2016;2:16057.
2. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. Journal of Clinical Endocrinology & Metabolism. 1999;84(6):1897–1899.
3. Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. Journal of the American Academy of Dermatology. 1993;29(4):568–575.
4. Famenini S, Gharavi NM, Beynet DP. Finasteride and spironolactone for the treatment of female pattern hair loss. Skin Therapy Letter. 2015;20(4):5–7.
5. Fried RG. Nonpharmacologic treatments in psychodermatology. Dermatologic Clinics. 2002;20(1):177–185.
6. Ibáñez L, et al. Low-dose pioglitazone, flutamide, and metformin for PCOS. Journal of Clinical Endocrinology & Metabolism. 2007;92(1):251–255.
7. Legro RS, et al. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2013;98(12):4565–4592.
8. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2004;150(2):186–194.
9. Randolph M, Tosti A. Oral minoxidil treatment for hair loss. Journal of the American Academy of Dermatology. 2021;84(3):737–746.
10. Teede HJ, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Nature Reviews Endocrinology. 2023;19:720–736.
11. Unfer V, et al. Myo-inositol effects in women with PCOS. Gynecological Endocrinology. 2017;33(7):509–514.